Core Viewpoint - A class action has been filed against Fortrea Holdings, Inc. for allegedly misleading investors regarding the progress of its pre-spin projects and financial expectations [1][2][4]. Group 1: Company Background - Fortrea Holdings, Inc. is a global contract research organization (CRO) that provides biopharmaceutical product and medical device development solutions [1]. - The company was spun off from Labcorp Holdings Inc. in June 2023 and operates under several transition services agreements with Labcorp [2]. Group 2: Financial Performance - On March 3, 2025, Fortrea announced that its revenue and adjusted EBITDA trajectories for 2025 were not in line with prior expectations, leading to a significant stock price drop of $3.47 per share, or 25.05%, closing at $10.38 [3]. - The company indicated that its pre-spin projects were late in their life cycle, resulting in lower revenue and profitability than expected for 2025 [3]. Group 3: Allegations and Misstatements - The complaint alleges that Fortrea overestimated the revenue contributions from pre-spin projects and overstated potential cost savings from exiting transition services agreements [4]. - It is claimed that the company's previously announced EBITDA targets for 2025 were inflated, which misrepresented the viability of its post-spin business model and financial prospects [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Fortrea Holdings Inc. for alleged violations of federal securities laws, with a deadline for investors to seek lead plaintiff status by August 1, 2025 [2][4]. Company Overview - Fortrea Holdings Inc. (NASDAQ: FTRE) is under scrutiny for allegedly making false or misleading statements regarding its financial performance and business model [4]. - The company has faced significant stock price declines following negative reports and announcements, indicating potential weaknesses in its business model and financial projections [5][6][7]. Financial Performance - Fortrea's stock price fell by $2.73 (12.29%) to $19.48 on September 25, 2024, after Jefferies downgraded the stock from buy to hold, citing concerns over the company's business model and cost savings [5]. - Following a downgrade by Baird Equity Research on December 6, 2024, the stock price dropped by $1.90 (8.06%) to $21.67, attributed to concerns about the company's communication and sector challenges [6]. - On March 3, 2025, Fortrea announced that its revenue and adjusted EBITDA expectations for 2025 were not aligned with prior forecasts, leading to a stock price decline of $3.47 (25.05%) to $10.38 [7]. Legal Proceedings - A federal securities class action has been filed against Fortrea, and investors who suffered losses are encouraged to contact Faruqi & Faruqi for potential legal recourse [2][4][9]. - The role of lead plaintiff in the class action is open to any member of the putative class, with the deadline for applications set for August 1, 2025 [8].

Core Viewpoint - A class action lawsuit has been filed against Fortrea Holdings, Inc. and certain officers for alleged violations of federal securities laws during the Class Period from July 3, 2023, to February 28, 2025, seeking damages for misleading statements regarding the company's business and financial prospects [1][6]. Company Overview - Fortrea is a global contract research organization (CRO) that provides biopharmaceutical product and medical device development solutions to various customers [4]. - The company was spun off from Labcorp Holdings Inc. in June 2023, becoming a standalone publicly traded entity [4]. - Fortrea claims to have the scale and expertise to deliver tailored solutions to its customers, with a focus on operational agility and financial flexibility [5]. Financial Performance and Projections - In March 2024, Fortrea targeted an adjusted EBITDA margin of approximately 13% for 2025, which was later revised to a range of 11% to 12% in August 2024, still representing a projected increase of 30% to 40% in adjusted EBITDA dollars [6]. - The lawsuit alleges that Fortrea overestimated revenue contributions from Pre-Spin Projects and overstated cost savings from exiting transition services agreements (TSAs), leading to inflated EBITDA targets [6]. Market Reactions and Analyst Reports - On September 25, 2024, Jefferies downgraded Fortrea from buy to hold, citing weaknesses in the business model amid pressure on biotechnology funding, resulting in a stock price drop of 12.29% [8]. - Following the cancellation of two scheduled conferences, Baird Equity Research downgraded Fortrea to neutral on December 6, 2024, leading to an 8.06% decline in stock price [9]. - On March 3, 2025, Fortrea announced that its revenue and adjusted EBITDA trajectories for 2025 were not aligned with prior expectations, causing a significant stock price drop of 25.05% [10]. Credit Rating and Future Outlook - After the Class Period, Fitch Ratings downgraded Fortrea, projecting a 2025 EBITDA margin of 7.0% to 8.0%, a significant decline from earlier targets of 13% and 11%-12% [11].

Core Viewpoint - A class action lawsuit has been filed against Fortrea Holdings Inc. for alleged violations of securities laws, claiming the company made false and misleading statements regarding its financial performance and business model [1][4]. Group 1: Lawsuit Details - The lawsuit is initiated by the Schall Law Firm, focusing on violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 [1]. - Investors who purchased Fortrea's securities between July 3, 2023, and February 28, 2025, are encouraged to participate in the lawsuit before the deadline of August 1, 2025 [2]. Group 2: Allegations Against Fortrea - The complaint alleges that Fortrea overestimated potential revenue from projects initiated before its spinoff from Labcorp Holdings Inc. [4]. - The company is accused of overstating cost savings from exiting transition services agreements, leading to inflated EBITDA targets [4]. - Overall, the lawsuit claims that Fortrea's public statements were materially misleading, resulting in investor losses when the truth was revealed [4].

Core Viewpoint - A lawsuit has been filed against Fortrea Holdings Inc. and its senior executives for potential violations of federal securities laws, stemming from allegations of overstating cost savings and revenue projections related to transition services agreements following its spin-off from Labcorp [1][2][4]. Group 1: Company Background - Fortrea Holdings Inc. is a global contract research organization that provides biopharmaceutical product and medical device development solutions. It was spun off into a standalone, publicly traded company by Labcorp Holdings Inc. in June 2023 [3]. Group 2: Allegations and Lawsuit Details - The lawsuit claims that Fortrea overstated the cost savings and margin improvements expected from exiting transition services agreements with Labcorp, as well as the revenue from pre-spin projects [4]. - The case is pending in the U.S. District Court for the Southern District of New York, titled Deslande v. Fortrea Holdings Inc., et al., No. 1:25-cv-04630 [2]. Group 3: Stock Performance and Market Reaction - Following a report from Jefferies on September 25, 2024, which indicated that Fortrea's anticipated cost savings were not as significant as previously thought, the stock price fell by $2.73, or over 12%, from $22.21 to $19.48 per share [5]. - On March 3, 2025, Fortrea announced disappointing Q4 and full year 2024 financial results, leading to a further decline in stock price by $3.47, or over 25%, from $13.85 to $10.38 per share [6].

Core Viewpoint - Fortrea Holdings Inc. is facing a class action securities lawsuit due to alleged securities fraud that affected investors between July 3, 2023, and February 28, 2025 [1][2]. Group 1: Allegations of Fraud - The lawsuit claims that Fortrea Holdings Inc. overestimated revenue contributions from its long-term projects, known as the Pre-Spin Projects, for the year 2025 [2]. - It is alleged that the company overstated potential cost savings from exiting transition services agreements, leading to inflated EBITDA targets for 2025 [2]. - The viability of Fortrea's post-spin-off business model and its financial prospects were reportedly overstated, resulting in materially false and misleading public statements [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until August 1, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [3]. - Class members may be entitled to compensation without incurring any out-of-pocket costs or fees, with no obligation to participate [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4].

NEW YORK, June 5, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action lawsuit on behalf of purchasers of Fortrea Holdings, Inc. (NASDAQ: FTRE) securities between July 3, 2023 and February 28, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 1, 2025.So what: If you purchased Fortrea securities during the Class ...

NEW YORK, June 05, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Fortrea Holdings, Inc. (“Fortrea” or “the Company”) (NASDAQ: FTRE) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Fortrea ...

Core Viewpoint - A class action lawsuit has been filed against Fortrea Holdings Inc. for allegedly misleading investors regarding its financial performance and business prospects following its spin-off from Labcorp Holdings Inc. [1][5] Group 1: Company Background - Fortrea Holdings Inc. was spun off from Labcorp Holdings Inc. in June 2023, becoming a standalone publicly traded company [3] - Following the spin-off, Fortrea entered into transition services agreements with Labcorp for various support services [3] Group 2: Financial Performance - On March 3, 2025, Fortrea announced that its revenue and adjusted EBITDA expectations for 2025 were not aligned with prior forecasts, leading to a significant stock price drop of $3.47 per share, or 25.05%, closing at $10.38 [4] - The company indicated that its Pre-Spin projects were underperforming and that post-spin work was not progressing quickly enough to compensate for the older projects' economic impact [4] Group 3: Allegations in the Lawsuit - The lawsuit claims that Fortrea overestimated revenue contributions from Pre-Spin projects and overstated potential cost savings from exiting transition services agreements [5] - It is alleged that the company's previously announced EBITDA targets for 2025 were inflated, misrepresenting the viability of its post-spin business model and financial prospects [5]

Core Viewpoint - Fortrea Holdings Inc. is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, with claims that the company and its executives made misleading statements regarding its financial performance and business model following its spin-off from Labcorp Holdings Inc. [1][3] Group 1: Class Action Lawsuit Details - The class action lawsuit is titled Deslande v. Fortrea Holdings Inc., and it includes purchasers of Fortrea securities from July 3, 2023, to February 28, 2025, with a deadline of August 1, 2025, to seek lead plaintiff status [1][2] - The lawsuit alleges that Fortrea overestimated revenue contributions from ongoing projects and overstated cost savings from exiting transition services agreements (TSAs), leading to inflated EBITDA targets for 2025 [3][4] Group 2: Financial Performance and Analyst Reports - On September 25, 2024, Jefferies downgraded Fortrea from buy to hold, citing weaknesses in its business model and stating that expected cost savings from exiting TSAs were not as significant as anticipated, resulting in a stock price drop of over 12% [4] - Following the cancellation of two scheduled conferences, Baird Equity Research downgraded Fortrea to neutral from outperform on December 6, 2024, leading to an additional stock price decline of more than 8% [5] - On March 3, 2025, Fortrea announced that its revenue and adjusted EBITDA projections for 2025 were not aligned with prior expectations, revealing that pre-spin projects were underperforming, which caused the stock price to fall over 25% [6] Group 3: Company Background - Fortrea is a global clinical research organization (CRO) that provides development solutions for biopharmaceutical products and medical devices, having been spun off from Labcorp in June 2023 [2][3]